Keytruda

Businessman climbing steps to pluck a star from the sky
Biotech

Merus hails 'unprecedented' survival on solid tumor bispecific

Merus reported a 79% 12-month survival rate, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.”
Nick Paul Taylor May 23, 2025 7:35am
Step closer race run

Immutep's LAG-3 agent posts 'impressive' survival data

May 5, 2025 10:37am
Flexibility and adaptation concept Arrows on cubes following a flexible path

'One of the lucky few': Bicara CEO on last year's $326M IPO

Apr 14, 2025 3:59pm
share price stock stock price shares falling falling

Pyxis' shares fall on lukewarm early ADC results in solid tumors

Nov 21, 2024 2:30pm
Graphic of arrows missing the target

Merck's LAG-3 combo fails colorectal cancer phase 3 study

Sep 25, 2024 8:35am
Male and female superheroes posing in fluttering cloaks

ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial

Sep 14, 2024 2:30am